Cargando…
[(18)F]AZD2461, an Insight on Difference in PARP Binding Profiles for DNA Damage Response PET Imaging
BACKGROUND: Poly (ADP-ribose) polymerase (PARP) inhibitors are extensively studied and used as anti-cancer drugs, as single agents or in combination with other therapies. Most radiotracers developed to date have been chosen on the basis of strong PARP1–3 affinity. Herein, we propose to study AZD2461...
Autores principales: | Guibbal, Florian, Hopkins, Samantha L., Pacelli, Anna, Isenegger, Patrick G., Mosley, Michael, Torres, Julia Baguña, Dias, Gemma M., Mahaut, Damien, Hueting, Rebekka, Gouverneur, Véronique, Cornelissen, Bart |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497465/ https://www.ncbi.nlm.nih.gov/pubmed/32342268 http://dx.doi.org/10.1007/s11307-020-01497-6 |
Ejemplares similares
-
Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [(18)F]olaparib in mouse models of glioma
por: Chan, Chung Ying, et al.
Publicado: (2022) -
PET Imaging of PARP Expression Using (18)F-Olaparib
por: Wilson, Thomas C., et al.
Publicado: (2019) -
Imaging PARP with [(18)F]rucaparib in pancreatic cancer models
por: Chan, Chung Ying, et al.
Publicado: (2022) -
Radiofluorination of a highly potent ATM inhibitor as a potential PET imaging agent
por: Fraser, Claudia Rose, et al.
Publicado: (2022) -
[(123)I]CC1: A PARP-Targeting, Auger Electron–Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer
por: Chan, Chung Ying, et al.
Publicado: (2023)